Grace Dy, MD

Articles by Grace Dy, MD

Tusamitamab Ravtansine Plus Ramucirumab as 2L Therapy or Beyond in Patients With Metastatic NSq NSCLC and High CEACAM5 Expression (CARMEN-LC04)

November 17th 2023

Grace Dy, MD, presents data from the CARMEN-LC04 study evaluating safety and anti-tumor activity of tusamitamab ravtansine combined with ramucirumab in high CEACAM5-expressing non-squamous cell (NSQ) NSCLC tumors.

Dr. Dy on the Use of Sotorasib in KRAS G12C–Mutated NSCLC

ByGrace Dy, MD

April 10th 2022

Grace Dy, MD, discusses the use of sotorasib in patients with non–small cell lung cancer with KRAS G12C mutations.

Latest Updated Articles

Dr. Dy on the Use of Sotorasib in KRAS G12C–Mutated NSCLC
April 10th 2022

Grace Dy, MD

Articles by Grace Dy, MD

Tusamitamab Ravtansine Plus Ramucirumab as 2L Therapy or Beyond in Patients With Metastatic NSq NSCLC and High CEACAM5 Expression (CARMEN-LC04)

Dr. Dy on the Use of Sotorasib in KRAS G12C–Mutated NSCLC

Latest Updated Articles

Trending on OncLive

HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA

TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC

Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis

SERENA-6 Meets PFS2 End Point With Early Switch to Camizestrant in ER+/HER2-Negative, ESR1-Mutated Advanced Breast Cancer

Dr Eads on Early Data for CDH17-Directed CAR T-Cell Therapy in R/R GI Cancers